Wasan Udayachalerm

DRUG-ELUTING STENTS FOR THE TREATMENT OF SMALL CORONARY ARTERY WITH DIABETES MELLITUS: A COMPARISON WITH SIROLIMUS, PACLITAXEL, ZOTAROLIMUS (ENDEAVOR RESOLUTE), BIOLIMUSA9, EPC CAPTURE AND EVEROLIMUS-ELUTING STENT: MULTICENTER REGISTRY IN ASIA

Aim: The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES), EPC capture (ECS) and Everolimus-eluting stent (EES) on the outcome of stenting in patients with diabetic very long coronary lesion (VLL) (lesion length ≥40 mm). Methods: A prospective analysis of 1317 patients with diabetic VLL (328 SES, 280 PES, 189 ZES-R, 190 BES, 143 ECS, 187 EES) was performed. The study endpoints were major adverse cardiac events (MACE) at 12 months, restenosis rate and target lesion revascularization (TLR) at 12 months. Results: See table for clinical results. Conclusion: (1) The use of drug-eluting stents in patients with diabetic VLL seems to be favorable in terms of in-hospital clinical outcome and long-term results. (2) Patients treated with BES and EES showed lesser restenosis rate and TLR compared with PES and ECS.

THE EFFECT OF DRUG-ELUTING STENTS ON CLINICAL AND ANGIOGRAPHIC OUTCOMES IN DIABETIC, PATIENTS, 2 YEARS RESULT: MULTICENTER REGISTRY IN ASIA

The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), EPC capture (ECS), Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES) and Everolimus-eluting stent (EES) on the outcome of percutaneous coronary intervention in patients with diabetes mellitus (DM